RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node Metastasis

Recruiting

Early Phase 1

RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node Metastasis

Sponsor:

Yana Najjar

Code:

NCT06216938

Conditions

Melanoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Vusolimogene oderparepvec (RP1)

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information